(Press-News.org) Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis.
Researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust analysed data from 36 Phase I trials run by the organisations' joint Drug Development Unit.
The study, published today in August's Annals of Oncology, found the overall risk to patients of suffering a life-threatening side-effect was around seven times less than for traditional cytotoxic agents*.
Most new cancer drugs developed over recent years are targeted agents, which attack the specific genetic or molecular faults driving cancer growth, rather than one-size-fits-all chemotherapeutics, which kill all rapidly dividing cells.
Recent studies have shown that patient response rates in Phase I trials of new-generation targeted drugs are approximately two-fold higher than for old-style drugs. But until now, the risk of side-effects to patients taking part in early stage trials of new-style drugs has been unclear.
Senior author Dr Rhoda Molife, a medical oncologist and senior investigator in Phase I clinical trials in the Drug Development Unit of The Institute of Cancer Research and The Royal Marsden, said: "Our study found that the risk of developing a serious side-effect in a Phase I trial of a targeted drug was relatively low, compared with previous analyses of similar trials of old-style chemotherapies.
"The theory behind targeted drugs is that they should affect only cancer cells that have a specific fault and spare healthy cells, which we hoped would lead to higher rates of efficacy and lower rates of side-effects. It's very pleasing that our study seems to back this up, at least in the context of Phase I trials."
"Importantly, we also identified characteristics that put patients at higher risk of these toxicities, including if they were sicker when joining the trial. This will help doctors make the right choices about who should be given new drugs in early stage clinical trials."
Scientists retrospectively analysed data from 687 patients treated at the Drug Development Unit of The Institute of Cancer Research and The Royal Marsden between January 2005 and December 2009. They had a range of cancer types, with gastrointestinal, gynaecological and sarcoma the most common.
The Drug Development Unit of The Institute of Cancer Research and The Royal Marsden is supported by the National Institute for Health Research Biomedical Research Centre for Cancer, and also receives funding from Cancer Research UK and the Experimental Cancer Medicine Centre network.
For targeted drugs, the most common toxicities were gastrointestinal – such as loss of appetite, diarrhoea and vomiting – and fatigue, while side-effects for cytotoxic drugs are generally haematological or cardiovascular in nature
Patients were more likely to suffer side-effects if they were given a higher dose than that which the trial later found to be optimal, or if they were sicker when they joined the trial. The findings should help guide researchers in selecting patients for trials and improving trial design.
Professor Alan Ashworth, Chief Executive of The Institute of Cancer Research, said: "The discovery of targeted therapies is revolutionising the way we treat cancer, and is a key focus of our research here at The Institute of Cancer Research. Many of these drugs have individually transformed the care of certain cancers, but the strength of this study is that it helps confirm the validity of the overall approach."
###
Media Contact: ICR Science Communications Manager Jane Bunce on 0207
153 5106 or 07 721 747 900
Notes to editors:
"Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience" with corresponding author L. R. Molife publishes in the August issue of the Annals of Oncology. For a copy of the paper please visit the ICR website.
* The overall risk to patients of suffering a Grade 4, life-threatening, side-effect in this study was 1.9 per cent, compared with 14 per cent found in an analysis of trials from 1991 to 2002. The risk of a Grade 3, severe, side-effect in this study was 14.1 per cent, compared to 10-36 per cent found across two previous analyses of Phase I trials of cytotoxic agents.
Phase I trials are designed to evaluate the drug's safety and also the optimal dose to give to patients. As these small trials represent the first time a drug has been tested in people, its effectiveness and side-effects are not yet known and so patients who are considering taking part face many uncertainties.
Although the specific side-effects of each drug will differ, understanding average responses is important so doctors can help patients evaluate whether to participate. Some side-effects are unavoidable as doctors try to establish the most appropriate dose for patients.
The Institute of Cancer Research (ICR) is one of the world's most influential cancer research institutes.
Scientists and clinicians at the ICR are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden Hospital and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.
The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment. The Cancer Therapeutics Unit and Drug Development Unit at the ICR and The Royal Marsden were recently honoured with the 2012 American Association for Cancer Research Team Science Award for the "tremendous impact" of their preclinical and clinical studies.
As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.
The ICR's mission is to make the discoveries that defeat cancer. For more information visit www.icr.ac.uk
The Royal Marsden NHS Foundation Trust
The Royal Marsden opened its doors in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education.
Today, together with its academic partner, The Institute of Cancer Research (ICR), it is the largest and most comprehensive cancer centre in Europe treating over 44,000 patients every year. It is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies. The Royal Marsden also provides community services in the London boroughs of Sutton and Merton and in June 2010, along with the ICR, the Trust launched a new academic partnership with Mount Vernon Cancer Centre in Middlesex.
Since 2004, the hospital's charity, The Royal Marsden Cancer Charity, has helped raise over £50 million to build theatres, diagnostic centres, and drug development units.
Prince William became President of The Royal Marsden in 2007, following a long royal connection with the hospital.
For more information, visit www.royalmarsden.nhs.uk
The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government's strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. For further information, visit the NIHR website (www.nihr.ac.uk).
This paper presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily
those of the NHS, the NIHR or the Department of Health.
The Experimental Cancer Medicine Centre Network
The Experimental Cancer Medicine Centre (ECMC) network is jointly supported by Cancer Research UK, the National Institute for Health Research in England, and the Departments of Health of Scotland, Wales and Northern Ireland. It launched in 2006, with £35M funding over five years, with a further £35M announced in 2011 for five more years to fund centres across the UK. Each ECMC brings together lab-based experts in cancer biology with cancer doctors to speed up the flow of ideas from the lab bench to the patient's bedside. Find out more at www.ecmcnetwork.org.uk
Cancer Research UK
Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research
The charity's groundbreaking work into the prevention, diagnosis and treatment of cancer has helped save millions of lives. This work is funded entirely by the public.
Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years.
Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1861 or visit www.cancerresearchuk.org. Follow us on Twitter and Facebook
Lower risk of serious side-effects in trials of new targeted drugs
2012-08-07
ELSE PRESS RELEASES FROM THIS DATE:
Study questions value of calcium and vitamin D supplements
2012-08-07
WINSTON-SALEM, N.C. – Aug. 7, 2012 – Prescribing calcium and vitamin D supplements for men at risk of bone loss from hormonal treatment for prostate cancer seems like good medicine.
But new research from epidemiologists at Wake Forest Baptist Medical Center showed that this type of supplementation did not prevent bone loss and, in fact, may increase the risk of cardiovascular disease and aggressive prostate cancer. The study was published online in the July issue of the journal The Oncologist.
"It wouldn't be so bad if there simply was no obvious benefit," said Gary ...
Children's healthy diets lead to healthier IQ
2012-08-07
Children fed healthy diets in early age may have a slightly higher IQ, while those on heavier junk food diets may have a slightly reduced IQ, according to new research from the University of Adelaide.
The study - led by University of Adelaide Public Health researcher Dr Lisa Smithers - looked at the link between the eating habits of children at six months, 15 months and two years, and their IQ at eight years of age.
The study of more than 7000 children compared a range of dietary patterns, including traditional and contemporary home-prepared food, ready-prepared baby ...
What makes Paris look like Paris? Carnegie Mellon software finds stylistic core
2012-08-07
PITTSBURGH—Paris is one of those cities that has a look all its own, something that goes beyond landmarks such as the Eiffel Tower or Notre Dame. Researchers at Carnegie Mellon University and INRIA/Ecole Normale Supérieure in Paris have developed visual data mining software that can automatically detect these sometimes subtle features, such as street signs, streetlamps and balcony railings, that give Paris and other cities a distinctive look.
The software analyzed more than 250 million visual elements gleaned from 40,000 Google Street View images of Paris, London, New ...
Should young men be vaccinated against human papilloma virus?
2012-08-07
New Rochelle, NY, August 7, 2012 — Vaccination against human papilloma virus (HPV) is recommended for young women to protect them from HPV infection and cervical cancer. Male HPV immunization is increasingly a topic of debate in the medical community. A timely review of the literature published in Viral Immunology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com), explores whether HPV vaccination of young men is warranted and cost effective. The article is available free online at the Viral Immunology (http://www.liebertpub.com/vim) ...
Study reveals impact of historical domestic cattle hybridization with American bison
2012-08-07
Plains bison are an iconic symbol of America on everything from coins to state flags. Now scientists writing in Conservation Biology are exploring how the cross-breeding of bison with domestic cattle in the late 1800s may still have unwanted effects on modern populations of the species.
"The plains bison are an iconic symbol of rugged individualism and the will to survive," said Professor James Derr from Texas A&M University. "The population crash and the spectacular recovery over the last 125 years is a classic example of the resilience of this species and the success ...
The economic cost of increased temperatures
2012-08-07
CAMBRIDGE, Mass. -- Even temporary rises in local temperatures significantly damage long-term economic growth in the world's developing nations, according to a new study co-authored by an MIT economist.
Looking at weather data over the last half-century, the study finds that every 1-degree-Celsius increase in a poor country, over the course of a given year, reduces its economic growth by about 1.3 percentage points. However, this only applies to the world's developing nations; wealthier countries do not appear to be affected by the variations in temperature.
"Higher ...
A simple way to help cities monitor traffic more accurately
2012-08-07
COLUMBUS, Ohio – Cities count the number of cars on the road in order to plan everything from the timing of stoplights to road repairs. But the in-road metal detectors that do the counting can make errors – most often by registering that a car is present when one isn't.
One common error is called "splashover" because it usually involves an over-sensitive detector picking up the presence a vehicle in the next lane over – as if the signal from the car "splashed over" into the adjacent lane.
Now Ohio State University researchers have developed software to help city managers ...
Greater working memory capacity benefits analytic, but not creative, problem-solving
2012-08-07
Psychological scientists have long known that the amount of information we can actively hold in mind at any given time – known as working memory – is limited. Our working memory capacity reflects our ability to focus and control attention and strongly influences our ability to solve problems.
In a new article in the August issue of Current Directions in Psychological Science, a journal of the Association for Psychological Science, Jennifer Wiley and Andrew Jarosz of the University of Illinois at Chicago explore the role of working memory capacity in both mathematical ...
Division of labor offers insight into the evolution of multicellular life
2012-08-07
EAST LANSING, Mich. — Dividing tasks among different individuals is a more efficient way to get things done, whether you are an ant, a honeybee or a human.
A new study by researchers at Michigan State University's BEACON Center for the Study of Evolution in Action suggests that this efficiency may also explain a key transition in evolutionary history, from single-celled to multi-celled organisms.
The results, which can be found in the current issue of the Proceedings of the National Academy of Sciences, demonstrate that the cost of switching between different tasks ...
BUSM/VA Boston Healthcare System investigators identify new gene linked to PTSD
2012-08-07
(Boston) – Investigators at Boston University School of Medicine (BUSM) and Veterans Affairs (VA) Boston Healthcare System have identified a new gene linked to post-traumatic stress disorder (PTSD). The findings, published online in Molecular Psychiatry, indicate that a gene known to play a role in protecting brain cells from the damaging effects of stress may also be involved in the development of PTSD.
The article reports the first positive results of a genome-wide association study (GWAS) of PTSD and suggests that variations in the retinoid-related orphan receptor ...